GlassScriptPhysician profile
Booker T Dalton
NPI 1477557130
$2,177.43
in general payments reported to CMS, 2019-2025
26 companies · $549 in 2025
The $549 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $41.92 · 2021: $207 · 2022: $434 · 2023: $402 · 2024: $433 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $363.45 | 2019-2025 | Xifaxan |
| Abbvie INC. | $362.59 | 2021-2025 | Linzess, Creon, Rinvoq |
| Janssen Biotech, INC. | $226.16 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Genzyme Corporation | $182.26 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $153.75 | 2021-2024 | Dificid |
| Madrigal Pharmaceuticals | $124.84 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $98.83 | 2022-2024 | Dupixent |
| Nestle Healthcare Nutrition INC. | $89.28 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.35 | 2024-2025 | Entyvio |
| Organon LLC | $54.51 | 2023-2025 | Renflexis, Hadlima |
| Olympus America INC. | $52.57 | 2024 | Evis Exera III Colonovideoscope |
| Amgen INC. | $47.23 | 2022 | |
| Qol Medical, LLC | $40.22 | 2019-2025 | Sucraid |
| Allergan, INC. | $36.71 | 2019 | |
| Medtronic, INC. | $34.03 | 2024 | Interstim |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $33.66 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $29.65 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $26.03 | 2025 | Iqirvo |
| Boston Scientific Corporation | $22.68 | 2025 | Cre Pro |
| Pfizer INC. | $22.53 | 2024 | |
| Redhill Biopharma INC. | $22.36 | 2022 | |
| Biocon Biologics INC | $21.57 | 2025 | Yesintek |
| Celltrion USA INC. | $21.40 | 2024 | Vegzelma |
| Ardelyx, INC. | $19.72 | 2025 | Ibsrela |
| Celgene Corporation | $15.36 | 2021 | |
| Intra-Sana Laboratories | $3.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Booker Dalton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.